Veracyte logo

VeracyteNASDAQ: VCYT

Profile

Sector:

Healthcare

Country:

United States

IPO:

30 October 2013

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$2.68 B
-29%vs. 3y high
84%vs. sector
-vs. 3y high
-vs. sector
-31%vs. 3y high
61%vs. sector
-67%vs. 3y high
66%vs. sector

Price

regular market | 9 min ago
$34.91+$0.53(+1.54%)

Dividend

No data over the past 3 years
$114.43 M$109.87 M
$114.43 M$5.73 M

Analysts recommendations

Institutional Ownership

VCYT Latest News

Veracyte: Revolutionizing Noninvasive Cancer Diagnostics
etftrends.com21 October 2024 Sentiment: POSITIVE

In this ROBO Global Artificial Intelligence Index spotlight, we focus on Veracyte (VCYT). The index underlies the $137 million ROBO Global Artificial Intelligence ETF (THNQ).

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
businesswire.com16 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and.

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
zacks.com09 September 2024 Sentiment: POSITIVE

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue?
zacks.com05 September 2024 Sentiment: POSITIVE

Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
businesswire.com26 August 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 2:35 p.m. Eastern Time. A live audio webcast of the company's presentation will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay o.

Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue?
zacks.com14 August 2024 Sentiment: POSITIVE

Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up
zacks.com08 August 2024 Sentiment: POSITIVE

Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
benzinga.com07 August 2024 Sentiment: POSITIVE

On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.

Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

Veracyte (VCYT) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.12 per share a year ago.

Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?
zacks.com17 July 2024 Sentiment: POSITIVE

Veracyte (VCYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  • 1(current)

What type of business is Veracyte?

Veracyte, Inc. is a leading company in the field of genomic diagnostics in the USA and abroad. The company was previously known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was registered in 2006, with headquarters located in South San Francisco, California. Veracyte, Inc. conducts a series of genomic tests for the detection of cancer and idiopathic pulmonary fibrosis in a CLIA-certified laboratory. The company uses advanced scientific methods such as whole transcriptome RNA sequencing and machine learning to develop tests and optimize analysis results.

What sector is Veracyte in?

Veracyte is in the Healthcare sector

What industry is Veracyte in?

Veracyte is in the Diagnostics & Research industry

What country is Veracyte from?

Veracyte is headquartered in United States

When did Veracyte go public?

Veracyte initial public offering (IPO) was on 30 October 2013

What is Veracyte website?

https://www.veracyte.com

Is Veracyte in the S&P 500?

No, Veracyte is not included in the S&P 500 index

Is Veracyte in the NASDAQ 100?

No, Veracyte is not included in the NASDAQ 100 index

Is Veracyte in the Dow Jones?

No, Veracyte is not included in the Dow Jones index

When was Veracyte the previous earnings report?

No data

When does Veracyte earnings report?

The next expected earnings date for Veracyte is 06 November 2024